Publications by authors named "J A D van der Woude"
Article Synopsis
- The study investigates the differences in anti-tumour necrosis factor (TNF) treatment response between pediatric (pIBD) and adult (aIBD) inflammatory bowel disease patients, highlighting that children often experience a loss of response in their first year on medication.
- Researchers conducted a prospective, observational study comparing biomarkers from both groups, monitoring treatment escalation and drug levels over 18 months.
- The findings revealed that treatment escalation occurred more frequently in pIBD patients, and while no biomarkers for maintained response were identified, nine pro-inflammatory proteins emerged as potential predictors for loss of response in this group.
Background: The International Consortium for Health Outcomes Measurement has selected the self-administered comorbidity questionnaire (SCQ) to adjust case-mix when comparing outcomes of inflammatory bowel disease (IBD) treatment between healthcare providers. However, the SCQ has not been validated for use in IBD patients.
Objectives: We assessed the validity of the SCQ for measuring comorbidities in IBD patients.
Preoperative screening and prehabilitation strategies prior to ileocolic resection in patients with Crohn's disease are not incorporated in routine care.
Int J Colorectal Dis
October 2023
Purpose: Recently, recommendations on perioperative care have been published to optimize postoperative outcomes in preoperative patients with inflammatory bowel disease. This study evaluated the current use of preoperative screening and prehabilitation strategies (PS) prior to elective ileocolic resection (ICR) in patients with Crohn's disease (CD).
Methods: Patients with CD who underwent an elective ICR were identified from a Dutch prospective cohort study.
Background: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated up to 12 months of treatment.
Aim: The aim of this study was to assess the effectiveness and safety of 24 months of tofacitinib use in UC patients in the Netherlands.
Background & Aims: Clinicians face difficulty in when and in what order to position biologics and Janus kinase inhibitors in patients with anti-tumor necrosis factor-alpha (TNF) refractory ulcerative colitis (UC). We aimed to compare the effectiveness and safety of vedolizumab and tofacitinib in anti-TNF-exposed patients with UC in our prospective nationwide Initiative on Crohn and Colitis Registry.
Methods: Patients with UC who failed anti-TNF treatment and initiated vedolizumab or tofacitinib treatment were identified in the Initiative on Crohn and Colitis Registry in the Netherlands.